Rossari Biotech Approves Q2 2026 Unaudited Results & ESOP Grant

Rossari Biotech Ltd's Board of Directors convened on July 18, 2026, approving the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026. The Board also approved the grant of 4000 stock options under the Rossari Employee Stock Option Plan - 2019 (ESOP 2019) and the allotment of 2500 equity shares pursuant to the exercise of options under the same plan. Additionally, the company approved the transfer of its 100% shareholding in Rossari International Limited Company to Rossari (Singapore) Pte. Ltd. as part of an internal group restructuring. The financial results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors.